UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Annals of oncology, 2020-07, Vol.31 (7), p.942-950

2020

Volltextzugriff (PDF)

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of oncology, 2022-04, Vol.33 (4), p.406-415

2022

Volltextzugriff (PDF)

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Annals of oncology, 2018-08, Vol.29 (8), p.1807-1813

2018

Volltextzugriff (PDF)

A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)

Annals of oncology, 2018-10, Vol.29, p.viii647-viii648

2018

Volltextzugriff (PDF)

Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

ESMO open, 2021-12, Vol.6 (6), p.100309, Article 100309

2021

Volltextzugriff (PDF)

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii410-viii410

2018

Volltextzugriff (PDF)

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)

Annals of oncology, 2018-10, Vol.29, p.viii645-viii646

2018

Volltextzugriff (PDF)

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

ESMO open, 2024-08, Vol.9 (8), p.103643, Article 103643

2024

Volltextzugriff (PDF)

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18

ESMO open, 2023-08, Vol.8 (4), p.101588, Article 101588

2023

Volltextzugriff (PDF)

Acquired resistance mechanisms to INC280, a MET inhibitor in MET-amplified lung cancer cells

European journal of cancer (1990), 2016-12, Vol.69, p.S135-S136

2016

Volltextzugriff (PDF)

Implication of Tumor Location on Lymph Node Metastasis in Carcinoma of Maxillary Sinus: Indication for Elective Nodal Treatment

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E376-E376

2016

Volltextzugriff (PDF)

2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012

European journal of cancer (1990), 2015-09, Vol.51, p.S579-S579

2015

Volltextzugriff (PDF)

153 Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.47-47

2012

Volltextzugriff (PDF)

Dose-Volume Predictors of Late Dysphagia after Definitive Radiotherapy in Larynx and Pharynx Cancer

International journal of radiation oncology, biology, physics, 2024-10, Vol.120 (2), p.e793-e794

2024

Volltextzugriff (PDF)

EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S330

2022

Volltextzugriff (PDF)

Seaweed processing using industrial single-mode cavity microwave heating: a preliminary investigation

Carbohydrate research, 2005-05, Vol.340 (7), p.1357-1364

2005

Volltextzugriff (PDF)

1491P PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients

Annals of oncology, 2023-10, Vol.34, p.S841-S842

2023

Volltextzugriff (PDF)

Safety and Activity Profile of Fianlimab (Anti–LAG-3) in Combination with Cemiplimab (Anti–PD-1) and Cemiplimab Monotherapy in Recurrent and/or Metastatic HNSCC

International journal of radiation oncology, biology, physics, 2024-10, Vol.120 (2), p.e742-e742

2024

Volltextzugriff (PDF)

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

The New England journal of medicine, 2023-11, Vol.389 (20), p.1851-1861

2023

Volltextzugriff (PDF)

PO-1235 Dose-volume predictors of dysphagia after definitive radiotherapy in larynx and hypopharynx cancer

Radiotherapy and oncology, 2023-05, Vol.182, p.S988-S989

2023

Volltextzugriff (PDF)

OD2-3 The effect of inpatient palliative care consultation on aggressiveness of antibiotic use at the end of life among patients with terminal cancer

ESMO open, 2022-12, Vol.7 (6), p.100659, Article 100659

2022

Volltextzugriff (PDF)

684TiP A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors

Annals of oncology, 2024-09, Vol.35, p.S532-S532

2024

Volltextzugriff (PDF)

W120 Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients

Clinica chimica acta, 2022-05, Vol.530, p.S336-S336

2022

Volltextzugriff (PDF)

5156 POSTER ABCB1 Single Nucleotide Polymorphismas a Possible Prognostic Factor in Breast Cancer Patients Receiving Docetaxel and Doxorubicin Neoadjuvant Chemotherapy on Systemic Treatment

European journal of cancer (1990), 2011, Vol.47, p.S376-S376

2011

Volltextzugriff (PDF)

EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S657-S658

2024

Volltextzugriff (PDF)

1 – 25 von 149

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(135)

Publikationsform

Artikel
(146)
Tagungsberichte
(3)

Sprache

Englisch
(149)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(43)
Life Sciences & Biomedicine
(28)
Humans
(17)
Oncology
(12)
Engineering
(11)
Engineering, Electrical & Electronic
(11)
Technology
(11)
Hematology, Oncology And Palliative Medicine
(10)
Applied Sciences
(8)
Cancer
(8)
Electronics
(8)
Exact Sciences And Technology
(8)
Circuit Properties
(7)
Electric, Optical And Optoelectronic Circuits
(7)
Prostate Cancer
(7)
Tumors
(7)
Male
(5)
Mutation
(5)
Proteomics
(5)
Animals
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)

Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18

Acquired resistance mechanisms to INC280, a MET inhibitor in MET-amplified lung cancer cells

Implication of Tumor Location on Lymph Node Metastasis in Carcinoma of Maxillary Sinus: Indication for Elective Nodal Treatment

2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012

153 Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

Dose-Volume Predictors of Late Dysphagia after Definitive Radiotherapy in Larynx and Pharynx Cancer

EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma

Seaweed processing using industrial single-mode cavity microwave heating: a preliminary investigation

1491P PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients

Safety and Activity Profile of Fianlimab (Anti–LAG-3) in Combination with Cemiplimab (Anti–PD-1) and Cemiplimab Monotherapy in Recurrent and/or Metastatic HNSCC

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

PO-1235 Dose-volume predictors of dysphagia after definitive radiotherapy in larynx and hypopharynx cancer

OD2-3 The effect of inpatient palliative care consultation on aggressiveness of antibiotic use at the end of life among patients with terminal cancer

684TiP A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors

W120 Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients

5156 POSTER ABCB1 Single Nucleotide Polymorphismas a Possible Prognostic Factor in Breast Cancer Patients Receiving Docetaxel and Doxorubicin Neoadjuvant Chemotherapy on Systemic Treatment

EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas

Aktive Filter

Suchergebnisse filtern